Evidence map›Paper›PMID 25512628›Full record

ArticleThe Journal of infectious diseases2015

Antiretroviral therapy in the elite controller: justified or premature?

Maile Y Karris, Richard H Haubrich

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Current Treatment Options for HIV Elite Controllers: a Review.Current treatment options in infectious diseases · 2018
    Article
  2. Article
  3. Curing HIV: Moving Forward Faster.AIDS research and human retroviruses · 2016
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Maile Y KarrisDepartment of Internal Medicine, University of California, San Diego.
Richard H HaubrichDepartment of Internal Medicine, University of California, San Diego.

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitU01AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BENSON, CONSTANCE ANN · 2007 to 2011
$19.3M
Efficacy of ART to Interrupt HIV Transmission NetworksR01MH100974 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2014 to 2018
$3.2M
Improving Antiretroviral Management for HIVK24AI064086 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HAUBRICH, RICHARD H · 2006 to 2015
$1.8M
NIAID NIH HHS AI064086NIAID NIH HHS AI 069432NIAID NIH HHS AI36214NIAID NIH HHS P30 AI036214NIMH NIH HHS R01-MH100974-01A1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

FemaleHIV InfectionsHospitalizationHumansMaleantiretroviral therapyelite controllersHIVoutcomes

Identifiers

PMID25512628

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.